Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)

McMaster University

$19,671.00

AMPK Mediated Prevention of Key INflammatory Abnormalities and Serious Events (AMP KINASE)

FY 2012-13

Summary
Over 50% of Canadians will have type 2 diabetes or cardiovascular disease (heart attack or stroke) in their lifetime. It is known that low levels of inflammation from immune cells can causes both type 2 diabetes and cardiovascular disease but we currently we don't know why this occurs or how to prevent it. In the current proposal we will examine the role for a metabolic sensing molecule, AMP-activated protein kinase (AMPK), in regulating inflammation and fat metabolism in immune cells. Importantly, AMPK is switched on by a number of commonly used and inexpensive drugs including aspirin and fish-oils, suggesting that these therapies may elicit beneficial effects on type 2 diabetes and cardiovascular disease by preventing inflammation; an idea that will be tested in over 12,000 susceptible individuals.
Program
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
276942
Name
Steinberg Gregory R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Projecttitle
AMPK Mediated Prevention of Key INflammatory Abnormalities and Serious Events (AMP KINASE)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$19,671
Cihrequipment2
$0
Programname2
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Keyworddelim
Amp-Activated Protein Kinase (Ampk); Cardiovascular Outcomes; Er Stress; Genetic Mouse Models; Inflammasome; Innate Immunity; Metabolism; Metformin; Origin Clinical Trial; Type 2 Diabetes
Abstract
Over 50% of Canadians will have type 2 diabetes or cardiovascular disease (heart attack or stroke) in their lifetime. It is known that low levels of inflammation from immune cells can causes both type 2 diabetes and cardiovascular disease but we currently we don't know why this occurs or how to prevent it. In the current proposal we will examine the role for a metabolic sensing molecule, AMP-activated protein kinase (AMPK), in regulating inflammation and fat metabolism in immune cells. Importantly, AMPK is switched on by a number of commonly used and inexpensive drugs including aspirin and fish-oils, suggesting that these therapies may elicit beneficial effects on type 2 diabetes and cardiovascular disease by preventing inflammation; an idea that will be tested in over 12,000 susceptible individuals.
Competitiondate
201211
Approvedterm2
1 yr 0 mth
Pinamesdelim
Steinberg, Gregory R; Gerstein, Hertzel C
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $19,671~ $0~